OSE Immunotherapeutics SA, of Nantes, France, published preclinical data for OSE-127, a monoclonal antibody targeting the IL-7 receptor (IL-7R), in Nature Communication. OSE-127 was shown to block two sites of IL-7R. Unlike antibodies that only bind to one site, OSE-127 didn't induce translational modifications of human peripheral blood mononuclear cells that are compatible with T-cell activation and inflammatory responses. OSE and its partner, Les Laboratoires Servier SAS, of Neuilly-sur-Seine, France, plan to move the drug into phase I development.